Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,105.50 | 5.60 | -0.06% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 24,910.63 | 8.10 | 0.03% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,020.58 | 225.72 | 0.55% |
| NZX 50 Index | 12,879.50 | 0.66 | -0.01% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,837.40 | 6.30 | -0.07% |
| SSE Composite Index | 3,633.99 | 16.40 | 0.45% |